跳至主要内容
临床试验/NCT03421340
NCT03421340已完成不适用

Prospective, Multi-center, Randomized Controlled Study Comparing Endoscopic Clearance of Non-Complex Biliary Stones Using Fluoroscopy/Radiation-Free Direct Solitary Cholangioscopy (DSC) to Standard of Care Endoscopic Retrograde Cholangiography (ERC)

Boston Scientific Corporation16 个研究点 分布在 4 个国家目标入组 250 人开始时间: 2018年9月21日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
250
试验地点
16
主要终点
Number of Participants With Complete Stone Clearance

研究概览

简要总结

To prospectively compare non-complex biliary stone clearance using fluoroscopy/radiation-free direct solitary cholangioscopy (DSC) utilizing the SpyGlass™ system with non-complex biliary stone clearance using standard endoscopic retrograde cholangiography (ERC).

详细描述

The objective of this study is to prospectively compare non-complex biliary stone clearance using fluoroscopy/radiation-free direct solitary cholangioscopy (DSC) utilizing the SpyGlass™ system with non-complex biliary stone clearance using standard endoscopic retrograde cholangioscopy (ERC).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Participant)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 18 years or older
  • Abdominal pain consistent with choledocholithiasis (procedure possible within 72 hours of onset of symptoms and imaging suggesting choledocholithiasis, contingent on persistent abdominal pain)
  • Abnormal LFTs
  • Non-complex biliary stone disease, defined as 5 or fewer stones in the common bile or common hepatic duct with largest stone no larger than 10 mm in size. If stones not seen on imaging (US, CT) the bile duct diameter should be ≤12 mm*
  • * Given the poor sensitivity (approximately 20%) for biliary stones of CT and US, the diameter of the dilated CBD is used as a surrogate for largest stone diameter
  • Availability of non-invasive imaging to determine the diameter of the bile duct and number and size of bile duct stones if visible on imaging
  • If probability of stones is high per investigator assessment based on ASGE criteria, any standard of practice imaging modality (eg. abdominal US) is acceptable.
  • If the probability of stones is either intermediate or low per investigator assessment based on ASGE criteria, MRCP or EUS imaging is required to confirm presence of stones.
  • Willing and able to comply with the study procedures and provide written informed consent to participate in the study

排除标准

  • Potentially vulnerable subjects, including but not limited to pregnant women and subjects in whom an endoscopic procedure is contraindicated
  • Location of the stones in intrahepatic ducts, cystic duct or proximal to strictures
  • Bile duct stricture noted distal to stone on MRCP, which would make extraction without lithotripsy impossible
  • Ongoing cholangitis at time of randomization, manifested by fever with tachycardia and hypotension or evidence of pus at the ampulla
  • Patients with prior biliary sphincterotomy
  • Patients with Primary Sclerosing Cholangitis (PSC)
  • Acute pancreatitis, defined as abdominal pain and serum concentration of pancreatic enzymes [lipase (required), amylase (optional)] three or more times the upper limit of normal
  • Surgically altered gastro-duodenal luminal anatomy other than prior Billroth I reconstruction, as these would be anticipated to lead to more complicated procedures
  • Coagulopathy or ongoing need for anti-coagulation

结局指标

主要结局

Number of Participants With Complete Stone Clearance

时间窗: 30 Days

Prospectively compare DSC vs. ERC

次要结局

  • Rate of Serious Adverse Events(30 Days)
  • Radiation Exposure(3 hours)
  • Duration of Procedure(3 hours)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (16)

Loading locations...

相似试验